Application No.: 09/988,292 Docket No.: PF160D2

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 18. (canceled)

19. (previously presented) An isolated human, humanized, or chimeric antibody or portion thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein whose sequence consists of amino acid residues 1 to 323 of SEQ ID NO:16;

(b) a protein consisting of a fragment of SEQ ID NO:16, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO:16; and

(c) a protein consisting of a fragment of SEQ ID NO:16, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO:16.

20. (original) The antibody or portion thereof of claim 19 that specifically binds protein (b).

21. (original) The antibody or portion thereof of claim 19 that specifically binds protein (c).

22. (original) The antibody or portion thereof of claim 19, wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

23. (original) The antibody or portion thereof of claim 19 which is a monoclonal antibody.

24. (original) The antibody or portion thereof of claim 19 which is a polyclonal antibody.

25. (original) The antibody or portion thereof of claim 19 which is a chimeric antibody.

26. (original) The antibody or portion thereof of claim 19 which is a humanized antibody.

27. (original) The antibody or portion thereof of claim 19 which is a human antibody.

28. (original) The antibody or portion thereof of claim 19 which is a single chain antibody.

29. (original) The antibody or portion thereof of claim 19 which is a Fab fragment.

PAGE 4/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18

30. (original) The antibody or portion thereof of claim 19 which is labeled.

31. (original) The antibody of claim 30, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

32. (original) A composition comprising the antibody or portion thereof of claim 19 and a carrier.

33. (original) The composition of claim 32, wherein the antibody or portion thereof is a monoclonal antibody.

34. (original) The composition of claim 32, wherein the antibody or portion thereof is a chimeric antibody.

35. (original) The composition of claim 32, wherein the antibody or portion thereof is a humanized antibody.

36. (original) The composition of claim 32, wherein the antibody or portion thereof is a human antibody.

37. (original) The composition of claim 32, wherein the antibody or portion thereof is a single chain antibody.

38. (original) The composition of claim 32, wherein the antibody or portion thereof is a Fab fragment.

39. (original) The composition of claim 32, wherein the antibody or portion thereof is labeled.

40. (original) The composition of claim 39, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

41. (original) An isolated cell that produces the antibody of claim 19.

42. (original) A hybridoma that produces the antibody of claim 19.

43. (original) A hybridoma that produces the antibody of claim 23.

44. (currently amended) A method of detecting the protein of SEQ ID NO:16 in a biological sample comprising:

PAGE 5/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18

(a) contacting the biological sample with the antibody or portion thereof of claim 19; and

(b) detecting the ~~present~~ presence of the antibody or portion thereof bound to the protein of SEQ ID NO:16 in the biological sample.

45. (original) The method of claim 44, wherein the antibody is a monoclonal antibody.

46. (original) The method of claim 44, wherein the antibody is a polyclonal antibody.

47. (original) The method of claim 44, wherein the antibody is a chimeric antibody.

48. (original) The method of claim 44, wherein the antibody is a humanized antibody.

49. (original) The method of claim 44, wherein the antibody is a human antibody.

50. (original) The method of claim 44, wherein the antibody is a single chain antibody.

51. (original) The method of claim 44, wherein the antibody is a labeled antibody.

52. (original) The method of claim 51, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

53. (previously presented) An isolated human, humanized, or chimeric antibody or portion thereof produced by immunizing an animal with a protein selected from the group consisting of:

(a) a protein whose sequence comprises amino acid residues 1 to 323 of SEQ ID NO:16;

(b) a protein whose sequence comprises at least 30 contiguous amino acid residues of SEQ ID NO:16; and

(c) a protein whose sequence comprises at least 50 contiguous amino acid residues of SEQ ID NO:16,

wherein said antibody or portion thereof specifically binds to the amino acid sequence of SEQ ID NO:16.

54. (original) The antibody or portion thereof of claim 53 produced by immunizing an animal with protein (a).

PAGE 6/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18

55. (original) The antibody or portion thereof of claim 53 produced by immunizing an animal with protein (b).

56. (original) The antibody or portion thereof of claim 53 produced by immunizing an animal with protein (c).

57. (previously presented) The antibody or portion thereof of claim 19 that specifically binds protein (a).

58. (original) The antibody or portion thereof of claim 57, wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

59. (original) The antibody or portion thereof of claim 57 which is a monoclonal antibody.

60. (original) The antibody or portion thereof of claim 57 which is a polyclonal antibody.

61. (original) The antibody or portion thereof of claim 57 which is a chimeric antibody.

62. (original) The antibody or portion thereof of claim 57 which is a humanized antibody.

63. (original) The antibody or portion thereof of claim 57 which is a human antibody.

64. (original) The antibody or portion thereof of claim 57 which is a single chain antibody.

65. (original) The antibody or portion thereof of claim 57 which is a Fab fragment.

66. (original) The antibody or portion thereof of claim 57 which is labeled.

67. (original) The antibody of claim 66, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

68. (original) A composition comprising the antibody or portion thereof of claim 57 and a carrier.

69. (original) The composition of claim 68, wherein the antibody or portion thereof is a monoclonal antibody.

70. (original) The composition of claim 68, wherein the antibody or portion thereof is a chimeric antibody.

PAGE 7/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18

71. (original) The composition of claim 68, wherein the antibody or portion thereof is a humanized antibody.

72. (original) The composition of claim 68, wherein the antibody or portion thereof is a human antibody.

73. (original) The composition of claim 68, wherein the antibody or portion thereof is a single chain antibody.

74. (original) The composition of claim 68, wherein the antibody or portion thereof is a Fab fragment.

75. (original) The composition of claim 68, wherein the antibody or portion thereof is labeled.

76. (original) The composition of claim 75, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

77. (original) An isolated cell that produces the antibody of claim 57.

78. (original) A hybridoma that produces the antibody of claim 57.

79. (original) A hybridoma that produces the antibody of claim 59.

80. (currently amended) A method of detecting the protein of SEQ ID NO:16 in a biological sample comprising:

(a) contacting the biological sample with the antibody or portion thereof of claim 57; and

(b) detecting the ~~present~~ presence of the antibody or portion thereof bound to the protein of SEQ ID NO:16 in the biological sample.

81. (original) The method of claim 80, wherein the antibody is a monoclonal antibody.

82. (original) The method of claim 80, wherein the antibody is a polyclonal antibody.

83. (original) The method of claim 80, wherein the antibody is a chimeric antibody.

84. (original) The method of claim 80, wherein the antibody is a humanized antibody.

85. (original) The method of claim 80, wherein the antibody is a human antibody.

PAGE 8/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18

86. (original) The method of claim 80, wherein the antibody is a single chain antibody.

87. (original) The method of claim 80, wherein the antibody is a labeled antibody.

88. (original) The method of claim 87, wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope; and

(c) a fluorescent label.

89. - 161. (canceled).

PAGE 9/10 * RCVD AT 11/19/2003 11:37:57 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:3013098439 * DURATION (mm-ss):02-18